Condition: Obesity and Cardiovascular Risk · Insulin Resistance · Obesity (Body Mass Index >30 kg/m2) · Sponsor: University Of Nigeria Teaching Hospital
Obesity is a chronic disease of global public health concern, contributing to cardiovascular disease, type 2 diabetes and certain cancers. Currently approved anti-obesity drugs and surgery are expensive and not readily available in Nigeria. Metformin, approved for type 2 diabetes, has been shown to promote weight loss among obese patients in high income countries. However, metformin's effects have not yet been demonstrated in Black African populations, which may have different genetic and environmental predispositions to obesity and to the effect of metformin. This blinded, placebo-controlled, randomized trial is determining the effect of metformin on weight loss, cardiovascular disease risk and insulin resistance in Black Nigerians.
This description comes directly from the study's public registry record.
Chiamaka C Onu, BSc · +2347031800855 · mowri2025@gmail.com
Always discuss trial participation with your own doctor first.
| Pathology Facility | Enugu, Enugu State, Nigeria | Recruiting |
| University of Nigeria Teaching Hospital | Enugu, Enugu State, Nigeria | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07297290